Higher dose requirements with insulin detemir in type 2 diabetes—Three cases and a review of the literature
- 31 May 2009
- journal article
- case report
- Published by Elsevier BV in Diabetes Research and Clinical Practice
- Vol. 84 (2), e24-e26
- https://doi.org/10.1016/j.diabres.2009.02.009
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetesDiabetologia, 2008
- Proportional Dose-Response Relationship and Lower Within-Patient Variability of Insulin Detemir and NPH Insulin in Subjects With Type 1 Diabetes MellitusExperimental and Clinical Endocrinology & Diabetes, 2007
- Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly Controlled Type 2 DiabetesClinical Therapeutics, 2006
- Time‐action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups*Diabetes, Obesity and Metabolism, 2006
- A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 DiabetesDiabetes Care, 2006
- The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human InsulinPharmaceutical Research, 2004
- Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 DiabetesDiabetes Care, 2004
- Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.Diabetes, 2000